Table 1 Comparison of baseline information for the training and testing sets
Level | Overall(1642) | training set (973) | testing set (669) | P-value | |
|---|---|---|---|---|---|
Age * | 43.69 (11.50) | 43.56 (11.45) | 43.89 (11.59) | 0.569 | |
Gender (%) | Male | 480 (29.2) | 286 (29.4) | 194 (29.0) | 0.906 |
Female | 1162 (70.8) | 687 (70.6) | 475 (71.0) | ||
Pathology type (%) | Papillary carcinoma | 1633 (99.5) | 969 (99.6) | 664 (99.3) | 0.571 |
Follicular carcinoma | 9 (0.5) | 6 (0.7) | 5 (0.7) | ||
Invasion (%) | No | 1145 (69.7) | 757 (77.8) | 388 (58.0) | < 0.001 |
Yes | 497 (30.3) | 216 (22.2) | 281 (42.0) | ||
Metastasis number # | 3 [2, 7] | 3 [1, 6] | 4 [2, 7] | < 0.001 | |
Benign lesion (%) | No | 696 (42.4) | 427 (43.9) | 269 (40.2) | 0.153 |
Yes | 946 (57.6) | 546 (56.1) | 400 (59.8) | ||
TNM stage (%) | I | 1382 (84.2) | 827 (85.0) | 555 (83.0) | 0.298 |
II-III | 260 (15.8) | 146 (15.0) | 114 (17.0) | ||
ATA risk stratification (%) | Low risk | 402 (24.5) | 257 (26.4) | 145 (21.7) | 0.033 |
Intermediate-high risk | 1240 (75.5) | 716 (73.6) | 524 (78.3) | ||
Tg (ng/mL) # | 2.2 [0.6,7.1] | 2.2[0.5,7.4] | 2.2[0.6,7.0] | 0.531 | |
Tg/TSH (ng/mIU) # | 24.7 [5.8,83.7] | 26.5[6.2,87.9] | 21.9[5.2,75.7] | 0.177 | |
conclusion (%) | ER | 787 (47.9) | 470 (48.3) | 317(47.4) | 0.752 |
NER | 855 (52.1) | 503 (51.7) | 352 (52.6) |